西罗莫司效果怎么样？

For patients undergoing kidney transplantation, it is recommended to be used in combination with cyclosporine and corticosteroids to prevent organ rejection. Sirolimus inhibits the activation and proliferation of T lymphocytes stimulated by antigens and cytokines (interleukins IL-2, IL-4 and IL-15). It also inhibits the production of antibodies. So, how effective is Biocon India’s sirolimus?

To clinically explore the clinical efficacy and safety of sirolimus in renal transplantation. Sirolimus was started within 48 hours after organ transplantation, with a loading dose of 6 mg and a maintenance dose of 2 mg. In the experiment, 23 patients with cadaveric kidney transplantation were given triple immunosuppressive therapy of sirolimus combined with cyclosporine and glucocorticoids.

Results: 22 patients completed 6-12 months of follow-up. The incidence rates of acute rejection (AR) at 6 and 12 months were 13.6% (3 cases/22 cases) and 15.8% (3 cases/19 cases) respectively. AR patients were reversed after pulse treatment with methylprednisolone and continued to be followed up for more than half a year. No recurrence of AR was found. The adverse reaction of taking sirolimus was hyperlipidemia (56.5%, 13 cases/23 cases). After reducing the dosage or applying lipid-lowering drugs, the patient's blood lipids dropped to normal or slightly higher than normal levels. Graft vascular disease and cardiovascular complications have not increased so far during follow-up.

Biocon is one of India's three largest biotech companies and an emerging global biopharmaceutical company that is committed to reducing the cost of treatment for chronic diseases such as diabetes, cancer and autoimmune disease patients by leveraging India's cost advantages and partners to provide affordable healthcare solutions to healthcare systems around the world.

It is an immunosuppressant that inhibits the activation and proliferation of T lymphocytes by inhibiting their response to stimulation by antigens and cytokines (IL-2, IL-4 and IL-15). For patients after kidney transplantation, sirolimus is an effective treatment option to prevent organ rejection.